Experience

Davis Polk advised EnVen Energy Corporation in connection with a Rule 144A/Regulation S offering of $325 million aggregate principal amount of its 11.000% senior secured second-lien notes…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 13,333,333 shares of common stock of ConforMis,…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 4,255,000 shares of common stock of…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 8,152,986 shares of common stock of…

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A offering of $172.5 million aggregate principal amount of its 1.00% convertible senior…

Davis Polk advised the CEO and co-founder of Schmidt’s Naturals in connection with the acquisition of Schmidt’s Naturals by Unilever. The transaction closed on December 31, 2017. …

Davis Polk advised the underwriter in connection with the SEC-registered offering of 7,500,000 shares of common stock of OneMain Holdings, Inc. sold by Springleaf Financial Holdings,…

Davis Polk advised the representatives of the underwriters in an SEC-registered public offering by Webster Financial Corporation of 6,000,000 depositary shares, each representing a 1/1…

Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000 shares of common stock of Editas Medicine, Inc. The common…